March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Hidehito Horinouchi: Amivantamab plus Lazertinib vs. Osimertinib in 1L EGFRm Advanced NSCLC
Mar 25, 2025, 19:50

Hidehito Horinouchi: Amivantamab plus Lazertinib vs. Osimertinib in 1L EGFRm Advanced NSCLC

Hidehito Horinouchi, Assistant Chief at National Cancer Center Hospital, shared on X:

Now Out:
MARIPOSA Study: Amivantamab plus Lazertinib vs. Osimertinib in 1L EGFRm Advanced NSCLC – Final OS Results
Presented by Prof. James Yang

  •  OS HR: 0.75 (95% CI: 0.61–0.92)
  •  Expected to extend median OS (mOS) by at least 12 months
  • NCT Number: NCT04487080″